東北大学

東北大学大学院医学系研究科
腎臓内科学分野
東北大学病院　腎臓・高血圧内科

論文・著書

～歴史ある論文・著書～

2024年

論文【英文】

  1. Latt KZ, Yoshida T, Shrivastav S, Abedini A, Reece JM, Sun Z, Lee H, Okamoto K, Dagur P, Heymann J, Zhao Y, Chung JY, Hewitt S, Jose PA, Lee K, He JC, Winkler CA, Knepper MA, Kino T, Rosenberg AZ, Susztak K, Kopp JB. HIV viral protein R induces loss of DCT1-type renal tubules. bioRxiv. 2023 Nov 13:2023.02.02.526686. doi: 10.1101/2023.02.02.526686.
  2. Mishima E. Constipation and high blood pressure variability. Hypertens Res. 2024 Feb;47(2):562-563. doi: 10.1038/s41440-023-01514-5. Epub 2023 Nov 20.
  3. Turcu AF, Tezuka Y, Lim JS, Salman Z, Sehgal K, Liu H, Larose S, Parksook WW, Williams TA, Cohen DL, Wachtel H, Zhang J, Dorwal P, Satoh F, Yang J, Lacroix A, Reincke M, Giordano TM, Udager AJ, Vaidya A, Rainey WE. Multifocal, Asymmetric Bilateral Primary Aldosteronism Cannot be Excluded by Strong Adrenal Vein Sampling Lateralization: An International Retrospective Cohort Study. Hypertension. 2024 Mar;81(3):604-613. doi: 10.1161/HYPERTENSIONAHA.123.21910. Epub 2024 Jan 4.
  4. Mishima E, Hirata Y. Membrane Dynamics and Cation Handling in Ferroptosis. Physiology (Bethesda). 2024 Mar 1;39(2):73-87. doi: 10.1152/physiol.00029.2023. Epub 2024 Jan 9.
  5. Tagawa K, Tsuru Y, Yokoi K, Aonuma T, Hashimoto J. Inverse association between obesity and aortic pressure augmentation is attenuated in women: the Wakuya study. J Hypertens. 2024 May 1;42(5):783-788. doi: 10.1097/HJH.0000000000003657. Epub 2024 Jan 15.
  6. Ishikawa Y, Yamazaki Y, Tezuka Y, Omata K, Ono Y, Tokodai K, Fujishima F, Kawanabe S, Katabami T, Ikeya A, Yamashita M, Oki Y, Nanjo H, Satoh F, Ito A, Unno M, Kamei T, Sasano H, Suzuki T. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity. J Steroid Biochem Mol Biol. 2024 Apr;238:106462. doi: 10.1016/j.jsbmb.2024.106462. Epub 2024 Jan 15.
  7. Nakayama M, Kabayama S, Miyazaki M. Application of Electrolyzed Hydrogen Water for Management of Chronic Kidney Disease and Dialysis Treatment-Perspective View. Antioxidants (Basel). 2024 Jan 11;13(1):90. doi: 10.3390/antiox13010090.
  8. Sato T, Yagi A, Yamauchi M, Kumondai M, Sato Y, Kikuchi M, Maekawa M, Yamaguchi H, Abe T, Mano N. The Use of an Antioxidant Enables Accurate Evaluation of the Interaction of Curcumin on Organic Anion-Transporting Polypeptides 4C1 by Preventing Auto-Oxidation. Int J Mol Sci. 2024 Jan 12;25(2):991. doi: 10.3390/ijms25020991.
  9. Wang Y, Harada-Shoji N, Kitamura N, Yamazaki Y, Ebata A, Amari M, Watanabe M, Miyashita M, Tada H, Abe T, Suzuki T, Gonda K, Ishida T. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer. Cancer Med. 2024 Jan;13(2):e6987. doi: 10.1002/cam4.6987.
  10. Suda A, Umaru BA, Yamamoto Y, Shima H, Saiki Y, Pan Y, Jin L, Sun J, Low YLC, Suzuki C, Abe T, Igarashi K, Furukawa T, Owada Y, Kagawa Y. Polyunsaturated fatty acids-induced ferroptosis suppresses pancreatic cancer growth. Sci Rep. 2024 Feb 22;14(1):4409. doi: 10.1038/s41598-024-55050-4.
  11. Oe Y. Editorial for the Special Issue: Pathophysiology of Chronic Kidney Disease and Its Complications. Biomedicines. 2024 Feb 10;12(2):416. doi: 10.3390/biomedicines12020416.
  12. Nakamura T, Ito J, Mourao ASD, Wahida A, Nakagawa K, Mishima E, Conrad M. A tangible method to assess native ferroptosis suppressor activity. Cell Rep Methods. 2024 Mar 25;4(3):100710. doi: 10.1016/j.crmeth.2024.100710. Epub 2024 Feb 24.
  13. Tanaka T, Maruyama S, Chishima N, Akiyama H, Shimamoto K, Inokuchi S, Yokota K, Ozaki A. Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study. Sci Rep. 2024 Mar 2;14(1):5172. doi: 10.1038/s41598-024-55827-7.
  14. Parksook WW, Brown JM, Omata K, Tezuka Y, Ono Y, Satoh F, Tsai LC, Niebuhr Y, Milks J, Moore A, Honzel B, Liu H, Auchus RJ, Sunthornyothin S, Turcu AF, Vaidya A. The Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study. J Clin Endocrinol Metab. 2024 Mar 7:dgae145. doi: 10.1210/clinem/dgae145.
  15. Tezuka Y, Omata K, Ono Y, Kambara K, Kamada H, Oguro S, Yamazaki Y, Gomez-Sanchez CE, Ito A, Sasano H, Takase K, Tanaka T, Katagiri H, Satoh F. Investigating the cut-off values of captopril challenge test for primary aldosteronism using the novel chemiluminescent enzyme immunoassay method: a retrospective cohort study. Hypertens Res. 2024 May;47(5):1362-1371. doi: 10.1038/s41440-024-01594-x. Epub 2024 Mar 8.
  16. Saigan M, Miyasaka M, Nagasawa T, Taguri M, Satomi N, Watahiki M, Nakashima M, Enta Y, Toki Y, Munehisa Y, Ito J, Hayatsu Y, Tada N. Transcatheter aortic valve replacement in patients with severe aortic stenosis reduced the frequency of intradialytic hypotension. Sci Rep. 2024 Mar 18;14(1):6479. doi: 10.1038/s41598-024-57213-9.
  17. Pintus G, Seccia TM, Amar L, Azizi M, Riester A, Reincke M, Widimsky J, Naruse M, Kocjan T, Negro A, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Lee BC, Chang CC, Wu VC, Kratka Z, Battistel M, Bagordo D, Caroccia B, Ceolotto G, Rossitto G, Rossi GP. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade. Hypertension. 2024 Jun;81(6):1391-1399. doi: 10.1161/HYPERTENSIONAHA.124.22721. Epub 2024 Mar 25.
  18. Mishima E. Targeting ferroptosis for treating kidney disease. Clin Exp Nephrol. 2024 Apr 22. doi: 10.1007/s10157-024-02491-w.
  19. Seibt T, Wahida A, Hoeft K, Kemmner S, Linkermann A, Mishima E, Conrad M. Ferroptosis Biology. Nephrol Dial Transplant. 2024 Apr 29:gfae097. doi: 10.1093/ndt/gfae097.
  20. Yong CC, Sakurai T, Kaneko H, Horigome A, Mitsuyama E, Nakajima A, Katoh T, Sakanaka M, Abe T, Xiao JZ, Tanaka M, Odamaki T, Katayama T. Human gut-associated Bifidobacterium species salvage exogenous indole, a uremic toxin precursor, to synthesize indole-3-lactic acid via tryptophan. Gut Microbes. 2024 Jan-Dec;16(1):2347728. doi: 10.1080/19490976.2024.2347728. Epub 2024 May 5.
  21. Ono Y, Tezuka Y, Omata K, Morimoto R, Yamazaki Y, Oguro S, Takase K, Ito A, Yoshimi T, Kojima S, Ito S, Sasano H, Suzuki T, Tanaka T, Katagiri H, Satoh F. Screening Cutoff Values for the Detection of Aldosterone-Producing Adenoma by LC-MS/MS and a Novel Noncompetitive CLEIA. J Endocr Soc. 2024 Apr 20;8(6):bvae080. doi: 10.1210/jendso/bvae080. eCollection 2024 Apr 6.
  22. Suzuki N, Iwamura Y, Kato K, Ishioka H, Konta Y, Sato K, Uchida N, Koida N, Sekine H, Tanaka T, Kumagai N, Nakai T. Crosstalk between oxygen signaling and iron metabolism in renal interstitial fibroblasts. J Clin Biochem Nutr. 2024 May;74(3):179-184. doi: 10.3164/jcbn.24-8. Epub 2024 Feb 28.
  23. Ono R, Takayama S, Abe M, Arita R, Abe T, Ishii T. Growth Differentiation Factor-15 Is Considered a Predictive Biomarker of Long COVID in Non-hospitalized Patients. Cureus. 2024 May 1;16(5):e59433. doi: 10.7759/cureus.59433. eCollection 2024 May.
  24. Saigan M, Miyasaka M, Nagasawa T, Taguri M, Satomi N, Watahiki M, Nakashima M, Enta Y, Toki Y, Munehisa Y, Ito J, Hayatsu Y, Tada N. Author Correction: Transcatheter aortic valve replacement in patients with severe aortic stenosis reduced the frequency of intradialytic hypotension. Sci Rep. 2024 Jun 5;14(1):12913. doi: 10.1038/s41598-024-63612-9.
  25. Abe M, Yamaguchi T, Koshiba S, Takayama S, Nakai T, Nishioka K, Yamasaki S, Kawaguchi K, Umeyama M, Masaura A, Ishizawa K, Arita R, Kanno T, Akaishi T, Miyazaki M, Abe T, Tanaka T, Ishii T; CKOALA study group. Oral alkalinizing supplementation suppressed intrarenal reactive oxidative stress in mild-stage chronic kidney disease: a randomized cohort study. Clin Exp Nephrol. 2024 Jun 13. doi: 10.1007/s10157-024-02517-3.
  26. Mimura I, Tanaka T, Nangaku M. Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease. Expert Opin Pharmacother. 2024 Jun 19. doi: 10.1080/14656566.2024.2370896.
  27. Latt KZ, Yoshida T, Shrivastav S, Abedini A, Reece JM, Sun Z, Lee H, Okamoto K, Dagur P, Ishimoto Y, Heymann J, Zhao Y, Chung JY, Hewitt S, Jose PA, Lee K, He JC, Winkler CA, Knepper MA, Kino T, Rosenberg AZ, Susztak K, Kopp JB. Single-nucleus RNA sequencing reveals loss of DCT1 renal tubules in HIV Vpr transgenic mice. Am J Pathol. 2024 Jul 18:S0002-9440(24)00237-2. doi: 10.1016/j.ajpath.2024.06.006.
  28. Suzuki N, Kanzaki M, Koide M, Izumi R, Fujita R, Takahashi T, Ogawa K, Yabe Y, Tsuchiya M, Suzuki M, Harada R, Ohno A, Ono H, Nakamura N, Ikeda K, Warita H, Osana S, Oikawa Y, Toyohara T, Abe T, Rui M, Ebihara S, Nagatomi R, Hagiwara Y, Aoki M. Sporadic inclusion body myositis-derived myotube culture revealed muscle cell-autonomous expression profiles. PLoS One. 2024 Aug 1;19(8):e0306021. doi: 10.1371/journal.pone.0306021. eCollection 2024.
  29. Maruyama S, Tanaka T, Akiyama H, Hoshino M, Inokuchi S, Kaneko S, Shimamoto K, Ozaki A. Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan. Clin Kidney J. 2024 Jul 30;17(8):sfae228. doi: 10.1093/ckj/sfae228. eCollection 2024 Aug.
  30. Yoshida T, Latt KZ, Rosenberg AZ, Santo BA, Myakala K, Ishimoto Y, Zhao Y, Shrivastav S, Jones BA, Yang X, Wang XX, Tutino VM, Sarder P, Levi M, Okamoto K, Winkler CA, Kopp JB. PKR activation-induced mitochondrial dysfunction in HIV-transgenic mice with nephropathy. Elife. 2024 Aug 29;12:RP91260. doi: 10.7554/eLife.91260.

論文【邦文】

  1. 長澤将：最新ガイドラインで学ぶ薬物療法の基本　慢性腎臓病（ＣＫＤ）　蛋白 ・ アルブミン尿を減らす薬物治療について学ぼう；日経ドラッグインフォメーション 2024年1月号 Page24-29
  2. 今田悠介、田中哲洋：【糖尿病性腎症研究の最前線】SGLT2阻害薬の新たな知見　SGLT2阻害薬の貧血治療効果と低酸素系への関与；腎と透析(0385-2156)96巻2号 Page229-233(2024.02)
  3. 田中哲洋、玉懸直人：【ガイドライン改訂で変わる　糖尿病関連腎臓病(DKD)診療】(第2章)糖尿病関連腎臓病の治療　薬物療法　貧血管理；jmed mook90号 Page68-73(2024.02)
  4. 三島英換：ビタミンKのフェロトーシス細胞死抑制作用の解明とビタミンK還元酵素の同定；ビタミン 98巻3号 Page91-96(2024.03)
  5. 長澤将：【最適な治療・管理がわかる　水・電解質・酸塩基平衡異常】総論　体液異常をより早期に察知する　体液量異常の病態を理解するための検査所見(血液・尿)の読み方；薬事(0016-5980)66巻5号 Page832-835(2024.04)
  6. 長澤将：【腎機能を考慮した内科疾患の診療】腎機能が病態・治療に関係する疾患　腎疾患　ネフローゼ症候群に伴う浮腫への対応と利尿薬の使い方；Medicina(0025-7699)61巻5号 Page674-677(2024.04)
  7. 玉懸直人、田中哲洋：【急性腎障害の最新トレンド】急性腎障害から慢性腎臓病への移行；臨床透析(0910-5808)40巻4号 Page388-393(2024.04)
  8. 宮崎真理子：【急性腎障害の最新トレンド】高齢者の急性腎障害；臨床透析(0910-5808)40巻4号 Page401-406(2024.04)
  9. 鈴木健弘、阿部 高明：【活性酸素と酸化ストレス】慢性腎臓病(CKD)と酸化ストレス；医学のあゆみ(0039-2359)289巻4号 Page253-256(2024.04)
  10. 長澤将、坂井正弘：腎臓内科　糖尿病非合併症アルブミン尿性CKD患者へのSGLT2阻害薬の注意点は?【非アルブミン尿であれば絶対適応ではないが,他のファクターを考慮して投与を検討する】；日本医事新報(0385-9215)5222号 Page57-58(2024.05)
  11. 石岡広崇、田中哲洋：【透析患者の心不全パンデミックに立ち向かう】腎性貧血と鉄欠乏による循環動態への影響；臨床透析(0910-5808)40巻5号 Page490-495(2024.05)
  12. 豊原敬文、渡邉駿、阿部高明：腸内細菌に着目した慢性腎臓病の動脈硬化に対する新規治療法の開発；臨床薬理の進歩(0914-4366)No.45 Page71-78(2024.06)
  13. 鈴木健弘、阿部 高明：特集 腎臓リハビリテーション　理論と実際 第5章　腎臓リハビリテーションのトピックス　5　腸腎連関ネットワークとCKD；臨床透析(0910-5808)40巻7号 Page980-989(2024.06)
  14. 宮崎真理子、藤倉恵美：特集 腎臓リハビリテーション　理論と実際 第3章　腎臓リハビリテーションの要素と実際　4　教育･日常生活指導　②血液透析患者；臨床透析(0910-5808)40巻7号 Page876-881(2024.06)
  15. 三島英換：【医学と医療の最前線】腎臓病におけるフェロトーシス細胞死；日本内科学会雑誌(0021-5384)113巻6号 Page1003-1010(2024.06)
  16. 長澤将：腎臓病・透析患者を受け持ったナースが最初に受けたい腎臓病の授業；エキスパートナース(0911-0194)40巻9号 Page18-50(2024.07)
  17. 中村俊崇、三島英換：特集 フェロトーシス(鉄依存性細胞死)--そのメカニズムの解明と,治療への応用 フェロトーシスの制御によるがん治療への応用；医学のあゆみ(0039-2359)290巻2号 Page164-169(2024.07)
  18. 長澤将：新規リン吸着薬（フォゼベル、テナパノル）について；宮城県腎臓協会会報 35号(2024.07)
  19. 鈴木健弘、阿部 高明：特集 2025年問題を乗り越える!　健康長寿社会に向けた疾患予防と治療戦略 健康長寿社会の実現に向けた治療戦略 健康長寿社会に向けたミトコンドリア先制医療；診断と治療(0370-999X)112巻8号 Page999-1004(2024.08)
  20. 三島英換：特集 今この研究が面白い! 第10章　腎臓 [腎臓病]腎臓病の治療標的としてのフェロトーシス細胞死；内科(0022-1961)134巻3号 Page793-798(2024.09)

著書【編集・監修・単独執筆】

  1. 長澤将：ヒットを狙え!Dr. 長澤に聞く腎臓病の薬の使い方；文光堂 2024年6月
TOP